Aclaris_Logo_CLR®.jpg
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update
May 07, 2021 07:00 ET | Aclaris Therapeutics, Inc.
 Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis Expected in Second Quarter of 2021Advancing ATI-450 with Planned Initiation of Phase 2b Trial for Moderate to Severe...
aclaris-final-logo-color.jpg
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
March 15, 2021 07:00 ET | Aclaris Therapeutics, Inc.
Enrollment CompletedData Expected Mid-Year 2021 WAYNE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on...
aclaris-final-logo-color.jpg
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
February 25, 2021 07:00 ET | Aclaris Therapeutics, Inc.
Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021ATI-450 Data Support New Oral Approach for the...
aclaris-final-logo-color.jpg
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
February 22, 2021 07:00 ET | Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
aclaris-final-logo-color.jpg
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
February 10, 2021 07:00 ET | Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
aclaris-final-logo-color.jpg
Aclaris Announces Pricing of Public Offering of Common Stock
January 20, 2021 08:45 ET | Aclaris Therapeutics, Inc.
WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
aclaris-final-logo-color.jpg
Aclaris Announces Proposed Public Offering of Common Stock
January 19, 2021 16:01 ET | Aclaris Therapeutics, Inc.
WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
aclaris-final-logo-color.jpg
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
January 19, 2021 07:00 ET | Aclaris Therapeutics, Inc.
Durable Clinical Activity over 12 Weeks was DemonstratedData Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid ArthritisATI-450, an...
aclaris-final-logo-color.jpg
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
December 15, 2020 07:00 ET | Aclaris Therapeutics, Inc.
New Scientific Advisory Board of Immuno-Inflammatory ExpertsPreliminary Topline Data for the ATI-450-RA-201 Trial Expected in January 2021 WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris...
aclaris-final-logo-color.jpg
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
November 16, 2020 16:01 ET | Aclaris Therapeutics, Inc.
WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...